Correction to: Acacia hydaspica R. Parker ameliorates cisplatin induced oxidative stress, DNA damage and morphological alterations in rat pulmonary tissue.

Following publication of the original article [1], the author reported that Tables 3 and 4 were incorrect due to a production error.

Correction to: BMC Complement Altern Med (2018) 18:49

https://doi.org/10.1186/s12906-018-2113-0

Following publication of the original article [1], the author reported that Tables 3 and 4 were incorrect due to a production error.

Table 3

Effect of cisplatin (CP) and different treatments of AHE on lung tissue antioxidant enzymes

Group	POD(U/min)	SOD(U/mg protein)	CAT(U/min)	QR(nM/min/mg protein)
Control	9.56 ± 0.635b	1.366 ± 0.038b	18.48 ± 0.058b	128.2 ± 0.81b
CP	5.03 ± 0.271a	0.765 ± 0.019a	10.83 ± 0.049a	83.99 ± 0.486a
AHE alone	10.29 ± 0.314b	1.358 ± 0.058b	18.57 ± 0.057b	128.9 ± 0.179b
CP + AHE	6.22 ± 0.128a, d	0.982 ± 0.035a,b*,d**	14.15 ± 0.083a,b, d	98.82 ± 1.232a.b, d
AHE + CP	9.18 ± 0.185b, c	1.255 ± 0.038b,c**	17.07 ± 0.026a,b, c	119.5 ± 1.283a,b, c
CP + Sily	9.20 ± 0.208b	1.262 ± 0.021b	17.14 ± 0.081a,b	119.9 ± 1.008a,b

Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Cisplatin (CP) group. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group. *, **: Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)

Table 4

Effect of cisplatin (CP) and different treatments of AHE on lungs tissue antioxidant enzymes and GSH profile

Group	GSH(μM/g tissue)	GR(nM/min/mg protein)	GST(nM/min/mg protein)	γ-GT(nM/min/mg Protein)	GPx(nM/min/mg Protein)
Control	16.12 ± 0.578b	143.7 ± 1.342b	98.85 ± 0.918b	295.4 ± 1.113b	107.4 ± 0.730b
CP	8.334 ± 0.356a	98.02 ± 0.619a	68.17 ± 0.962a	82.82 ± 0.958a	54.08 ± 0.909a
AHE alone	6.38 ± 0.207b	144.0 ± 1.492b	99.79 ± 1.865 b	295.6 ± 0.599b	108.8 ± 1.216b
CP + AHE	11.99 ± 0.305a,b, d	116.9 ± 0.813a,b,d	78.34 ± 1.076a,b**,d**	137.8 ± 1.017a,b,d	71.28.8 ± 0.501a,b,c
AHE + CP	15.63 ± 0.532b, c	135.0 ± 0.393 a,b,c	89.65 ± 1.49 a**,b,c	261.4 ± 0.802a,b,c	92.78 ± 1.216a,b,c
CP + Sily	15.29 ± 0.312b	133.8 ± 1.25 a,b	87.60 ± 1.644a,b	264.3 ± 1.067a,b	95.64 ± 1.573a,b

Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Cisplatin (CP) group. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group. *, **: Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)

The corrected tables are given below.